Cochrane · systematic review · CD011076
Dimethyl fumarate for multiple sclerosis
Xu, Z, Zhang, F, Sun, F, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 3 · 75%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Dimethyl fumarate for multiple sclerosis
Population: Patients with relapsing‐remitting multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
The proportion of patients with at least one relapse at two years | RR 0.64 [0.54, 0.77] | 2 studies · 1540 participants | Moderate |
The proportion of patients with disability worsening at two years | RR 0.65 [0.53, 0.81] | 2 studies · 1539 participants | Low |
The proportion of patients who discontinued study drug because of adverse events excluding relapses at two years | RR 2.18 [1.56, 3.06] | 2 studies · 1540 participants | Moderate |
The proportion of patients with lymphopenia at two years | RR 5.69 [2.4, 13.46] | 2 studies · 1540 participants | Moderate |